GRUPOS DE INVESTIGACIÓN

Proyectos

• A retrospective cohort study to assess drug utilisation and long-term safety of galcanezumab in European patients in the course of routine clinical care

  Investigador Principal: Daniel Prieto Alhambra

  Entidad Financiadora: (2019 - 2022)

• A retrospective cohort study to assess modification of VKA and DOAC treatment effectiveness and safety among patients with atrial fibrillation in three countries

  Investigador Principal: Daniel Prieto Alhambra

  Entidad Financiadora: (2019 - 2022)

• Advanced data analysis and management systems (Big Data solutions) in the identification and assessment of frailty risk profiles in populations, their evolution to disability, and their treatment

  Entidad Financiadora: (2017 - 2020)

• Asociación entre el uso de fármacos anti-osteoporosis y medicamentos anti-diabéticos y riesgo de fractura sintomática en pacientes con Diabetes Mellitus tipo 2

  Entidad Financiadora: (2015 - 2017)

• Asociación entre los niveles de vitamina D en sangre, los suplementos con vitamina D y las fracturas osteoporóticas en la población catalana: estudio de base poblacional

  Investigador Principal: Reyes Reyes, Carlen

  Entidad Financiadora: (2023)

• Characterisation and risks of long-term COVID-19 outcomes using large real world data

  Investigador Principal: Talita Duarte Salles

  Entidad Financiadora: (2022)

Publicaciones recientes

• Markus AF, Rijnbeek PR, Kors JA, Burn E, Duarte-Salles T, Haug M, Kim C, Kolde R, Lee Y, Park HS, Park RW, Prieto-Alhambra D, Reyes C, Krishnan JA, Brusselle GG, Verhamme KM. Real-world treatment trajectories of adults with newly diagnosed asthma or COPD. BMJ Open Respir Res. 2024 Feb; 11(1). doi:10.1136/bmjresp-2023-002127. Epub 2024 Feb 27. pmc:PMC10900306. PMID:38413124.

• Gauffin O, Brand JS, Vidlin SH, Sartori D, Asikainen S, Català M, Chalabi E, Dedman D, Danilovic A, Duarte-Salles T, García Morales MT, Hiltunen S, Jödicke AM, Lazarevic M, Mayer MA, Miladinovic J, Mitchell J, Pistillo A, Ramírez-Anguita JM, Reyes C, Rudolph A, Sandberg L, Savage R, Schuemie M, Spasic D, Trinh NTH, Veljkovic N, Vujovic A, de Wilde M, Zekarias A, Rijnbeek P, Ryan P, Prieto-Alhambra D, Norén GN. Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network Study. Drug Saf. 2023 Dec; 46(12):1335-1352. doi:10.1007/s40264-023-01353-w. Epub 2023 Oct 07. pmc:PMC10684396. PMID:37804398.

• Raventós B, Fernández-Bertolín S, Aragón M, Voss EA, Blacketer C, Méndez-Boo L, Recalde M, Roel E, Pistillo A, Reyes C, van Sandijk S, Halvorsen L, Rijnbeek PR, Burn E, Duarte-Salles T. Transforming the Information System for Research in Primary Care (SIDIAP) in Catalonia to the OMOP Common Data Model and Its Use for COVID-19 Research. Clin Epidemiol. 2023 ; 15:969-986. doi:10.2147/CLEP.S419481. Epub 2023 Sep 13. pmc:PMC10505380. PMID:37724311.

• Premi SEE-CIBER a les Millors Comunicacions presentades per personal investigador jove. SEEP 2023. Impact of the COVID-19 pandemic on prescription trends of psychotropic medications CO25 COVID-19 IV. Raventós B, Reyes C, Aragonès E, Prieto D, Duarte-Salles T.

• Raventós B, Reyes C, Aragonès E, Prieto D, Duarte-Salles T. Póster. Impact of the COVID-19 pandemic on prescription trends of psychotropic medications CO25 COVID-19 IV. Sociedad Esañola de Epidemiologia 2023. 10/05/2023, Porto (Portugal).

• Tan EH, Robinson DE, Jödicke AM, Mosseveld M, Bødkergaard K, Reyes C, Moayyeri A, Voss A, Marconi E, Lapi F, Reinold J, Verhamme KMC, Pedersen L, Braitmaier M, de Wilde M, Ruiz MF, Aragón M, Bosco-Levy P, Lassalle R, Prieto-Alhambra D, Sanchez-Santos MT. Drug utilization analysis of osteoporosis medications in seven European electronic health databases. Osteoporos Int. 2023 Oct; 34(10):1771-1781. doi:10.1007/s00198-023-06837-0. Epub 2023 Jul 12. pmc:PMC10511353. PMID:37436441.